EPIGENOMICS AG |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.785 EUR | -1.92% |
|
+9.51% | -4.03% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
| Sales 2024 * | - | Sales 2025 * | - | Capitalization | 1.44M 1.55M 2.12M |
|---|---|---|---|---|---|
| Net income 2024 * | - 0 0 | Net income 2025 * | - 0 0 | EV / Sales 2024 * | - |
| Net cash position 2024 * | 2.48M 2.67M 3.65M | Net cash position 2025 * | 1.39M 1.49M 2.04M | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-1.84
x | P/E ratio 2025 * |
-2.87
x | Employees | - |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 66.77% |
More Fundamentals
* Assessed data
More press releases
More news
| 1 day | -1.92% |
| Managers | Title | Age | Since |
|---|---|---|---|
Frederic Hilke
IRC | Investor Relations Contact | - | - |
Annett Dietrich
HRO | Human Resources Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Helge Lubenow
CHM | Chairman | 56 | 16-05-24 |
Jochen Hummel
BRD | Director/Board Member | 54 | 02-04 |
Alexander Link
BRD | Director/Board Member | 53 | 20-05-31 |
Epigenomics AG is a Germany-based molecular diagnostics company focused on blood-based detection, prognosis and monitoring of cancers using deoxyribonucleic acid (DNA) methylation technology. It develops and commercializes blood-based diagnostic products across multiple cancer indications. The Company's main product is Epi proColon, a blood test for colorectal cancer screening. Along with the blood-based tests the Company offers services related to research, product development, regulatory approval and manufacturing of in-vitro diagnostic (IVD) products. It also offers Epi proLung, a blood-based test that detects the presence of lung cancer in blood plasma. The Company is present in Europe and the United States.
Calendar
2024-05-28
- Annual General Meeting
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
1.64
EUR
Average target price
15.8
EUR
Spread / Average Target
+863.41%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -27.67% | 9.87B | |
| -17.30% | 2.73B | |
| -11.15% | 2.24B | |
| -22.32% | 1.63B | |
| +59.69% | 1.39B | |
| +23.58% | 771M | |
| -1.31% | 760M | |
| -28.57% | 516M | |
| +5.37% | 310M |
- Stock Market
- Equities
- ECX Stock
- ECX Stock
